Effect of Neuromuscular Blockade Reversal With Sugammadex on Oxygenation, Pain and Arousal States in the Post Anesthesia Care Unit

Trial Profile

Effect of Neuromuscular Blockade Reversal With Sugammadex on Oxygenation, Pain and Arousal States in the Post Anesthesia Care Unit

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Aug 2016

At a glance

  • Drugs Sugammadex (Primary) ; Neostigmine
  • Indications Neuromuscular blockade
  • Focus Therapeutic Use
  • Acronyms Neuropa
  • Most Recent Events

    • 14 Aug 2016 Status changed from recruiting to completed.
    • 07 Dec 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Mar 2016 as reported by ClinicalTrials.gov.
    • 31 Aug 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top